Related references
Note: Only part of the references are listed.The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron
Youchun Wang et al.
EMERGING MICROBES & INFECTIONS (2022)
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials
Fengcai Zhu et al.
LANCET RESPIRATORY MEDICINE (2022)
A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2
Junyu Chen et al.
SCIENCE BULLETIN (2022)
Characteristics of SARS-CoV-2 and COVID-19
Ben Hu et al.
NATURE REVIEWS MICROBIOLOGY (2021)
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine
J. Sadoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Global production capacity of seasonal and pandemic influenza vaccines in 2019
Erin Sparrow et al.
VACCINE (2021)
A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike
Mijia Lu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses
Weina Sun et al.
NATURE COMMUNICATIONS (2021)
A live measles-vectored COVID-19 vaccine induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamsters
Phanramphoei N. Frantz et al.
NATURE COMMUNICATIONS (2021)
COVID-19 Vaccines vs Variants-Determining How Much Immunity Is Enough
Rita Rubin
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
Kevin O. Saunders et al.
NATURE (2021)
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
Dapeng Li et al.
CELL (2021)
Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic
Samir Andrade Mendonca et al.
NPJ VACCINES (2021)
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
Petra Mlcochova et al.
NATURE (2021)
Next-generation influenza vaccines: opportunities and challenges
Chih-Jen Wei et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
Wanbo Tai et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Jun Lan et al.
NATURE (2020)
Lessons for COVID-19 Immunity from Other Coronavirus Infections
Alan Sariol et al.
IMMUNITY (2020)
SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
Gregory A. Poland et al.
LANCET (2020)
SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function (vol 51, pg 831, 2020)
Emma S. Winkler et al.
NATURE IMMUNOLOGY (2020)
Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice
Andrea N. Loes et al.
VIRUSES-BASEL (2020)
A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity
Angkana T. Huang et al.
NATURE COMMUNICATIONS (2020)
Full-length three-dimensional structure of the influenza A virus M1 protein and its organization into a matrix layer
Lisa Selzer et al.
PLOS BIOLOGY (2020)
A systematic review of SARS-CoV-2 vaccine candidates
Yetian Dong et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Non-lytic clearance of influenza B virus from infected cells preserves epithelial barrier function
Rebekah E. Dumm et al.
NATURE COMMUNICATIONS (2019)
The Development and Use of Reporter Influenza B Viruses
Rebekah E. Dumm et al.
VIRUSES-BASEL (2019)
Influenza vaccines: Evaluation of the safety profile
Claudia Maria Trombetta et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
Efforts to Improve the Seasonal Influenza Vaccine
Alfred T. Harding et al.
VACCINES (2018)
Rationally Designed Influenza Virus Vaccines That Are Antigenically Stable during Growth in Eggs
Alfred T. Harding et al.
MBIO (2017)
Reverse Genetics Approaches for the Development of Influenza Vaccines
Aitor Nogales et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection
Kyra D. Zens et al.
JCI INSIGHT (2016)
Current and next generation influenza vaccines: Formulation and production strategies
Peter C. Soema et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2015)
Investigating Influenza A Virus Infection: Tools To Track Infection and Limit Tropism
Jessica K. Fiege et al.
JOURNAL OF VIROLOGY (2015)
Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology
Yoshikazu Honda-Okubo et al.
JOURNAL OF VIROLOGY (2015)
Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines
Saranya Sridhar et al.
VACCINES (2015)
Influenza Viruses with Rearranged Genomes as Live-Attenuated Vaccines
Lindomar Pena et al.
JOURNAL OF VIROLOGY (2013)
In Vivo Bioluminescent Imaging of Influenza A Virus Infection and Characterization of Novel Cross-Protective Monoclonal Antibodies
Nicholas S. Heaton et al.
JOURNAL OF VIROLOGY (2013)
Engineering influenza viral vectors
Junwei Li et al.
BIOENGINEERED (2013)
Intranasal Immunization with a Formalin-Inactivated Human Influenza A Virus Whole-Virion Vaccine Alone and Intranasal Immunization with a Split-Virion Vaccine with Mucosal Adjuvants Show Similar Levels of Cross-Protection
Shigefumi Okamoto et al.
CLINICAL AND VACCINE IMMUNOLOGY (2012)
Live and Inactivated Influenza Vaccines Induce Similar Humoral Responses, but Only Live Vaccines Induce Diverse T-Cell Responses in Young Children
Daniel F. Hoft et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
A Nine-Segment Influenza A Virus Carrying Subtype H1 and H3 Hemagglutinins
Qinshan Gao et al.
JOURNAL OF VIROLOGY (2010)
Economic evidence of influenza vaccination in children
Emmanuelle Savidan et al.
HEALTH POLICY (2008)
Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines
Qing He et al.
IMMUNOLOGY (2007)
Live attenuated versus inactivated influenza vaccine in infants and young children
Robert B. Belshe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Comparison of the influenza virus-specific effector and memory C-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines
Sanae Sasaki et al.
JOURNAL OF VIROLOGY (2007)
Influenza virus NS vectors expressing the Mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge
Sabine Sereinig et al.
CLINICAL AND VACCINE IMMUNOLOGY (2006)
Addition of a prominent epitope affects influenza a virus-specific CD8(+) T cell immunodominance hierarchies when antigen is limiting
Misty Rayna Jenkins et al.
JOURNAL OF IMMUNOLOGY (2006)
Share Paper
